NOVEL HEXANUCLEAR ARENE-RUTHENIUM NANO PRISMATIC CAGE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER AS ACTIVE INGREDIENT

摘要

PURPOSE: A pharmaceutical composition containing hexanuclear arene-ruthenium nano prismatic cage compound is provided to suppress the proliferation of human SK-hep-1(liver cancer), HeLa(ovarian cancer), HCT-15(colorectal cancer), A549(lung cancer), and MDA-MB-231(breast cancer) cells and to ensure excellent anticancer effect. CONSTITUTION: A novel hexanuclear nanoprismatic cage compound is denoted by chemical formula 1. A method for preparing the compound of chemical formula 1 comprises: a step of reacting half sandwich arene ruthenium metal receptors(3 or 4) and tri(pyridylethynyl)benzene(2) under the presence of a reaction solvent; and a step of adding diethyl ether to a reaction mixture to prepare a self-assembly compound of chemical formula 1. The reaction solvent is a methanol-dichloromethane solution. A pharmaceutical composition for preventing and treating cancer contains the compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.